What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment

The analysis found preference for interventions with maximum benefits while minimizing costs. Respondents preferred studies with longer follow-up time for reimbursement decisions despite consequent treatment delays. Notably, respondents were willing to accept the uncertainty associated with surrogate outcomes-reflected through study length and completeness of evidence-provided the intervention demonstrated a favorable ICER.